Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery

This study has been completed.
Information provided by:
Allergan Identifier:
First received: August 30, 2007
Last updated: September 29, 2009
Last verified: August 2009
This is a 16-day study to evaluate the safety and efficacy of ketorolac eye drops for the treatment of inflammation and pain associated with cataract surgery.

Condition Intervention Phase
Cataract Extraction
Drug: ketorolac
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Resolution of Post Operative Inflammation [ Time Frame: Day 14 ]

Secondary Outcome Measures:
  • Ocular Pain [ Time Frame: Day 1 ]
  • Mean Pupil Area [ Time Frame: Day 0 ]

Enrollment: 248
Study Start Date: October 2007
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: ketorolac

Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.


Placebo Comparator: 2 Drug: ketorolac

Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.



Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients undergoing cataract surgery

Exclusion Criteria:

  • Uncontrolled ocular disease in cataract surgery eye
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00524264

United States, California
Artesia, California, United States
Sponsors and Collaborators
Study Director: Medical Director Allergan
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Therapeutic Area Head, Allergan, Inc. Identifier: NCT00524264     History of Changes
Other Study ID Numbers: 191578-005
Study First Received: August 30, 2007
Results First Received: August 19, 2009
Last Updated: September 29, 2009

Additional relevant MeSH terms:
Pathologic Processes
Lens Diseases
Eye Diseases
Ketorolac Tromethamine
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017